Clinical Trial

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Study acronym: EXAFIP2
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 2, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-12-29; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2023-10-27
Trial Details
NCT Number NCT05674994
Lead Sponsor Fondation Hôpital Saint-Joseph
Conditions Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Enrollment 110 participants
Start Date 2023-10-26
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-02